Failure is one of the hardest things in life -- and it’s a near-certainty in drug development. When he founded the Alzheimer’s company Axovant, Vivek Ramaswamy expressed high confidence that a drug it was developing, intepirdine, would help Alzheimer’s patients. On Tuesday, he had to face the inescapable fact that he was wrong.
